| MIR489 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | MIR489, MIRN489, hsa-mir-489, mir-489, microRNA 489 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 614523 GeneCards: MIR489 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
MicroRNA 489 is a miRNA that in humans is encoded by the MIR489 gene.[3]
Function
microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into an RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. miR-489 acts as tumor suppressor miRNA in breast cancer by inhibiting various oncogenic signaling pathway. It has been demonstrated miR-489 target HER2 and LAPTM4b by directly binding to their 3'UTR. Role of miR-489 has been studied in autochatothus MMTV-Her2 mouse model.[4]
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000207656 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Entrez Gene: MicroRNA 489".
- ↑ Patel Y, Shah N, Lee JS, Markoutsa E, Jie C, Liu S, Botbyl R, Reisman D, Xu P, Chen H (April 2016). "A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth". Oncotarget. 7 (14): 18295–308. doi:10.18632/oncotarget.7577. PMC 4951289. PMID 26918448.
Further reading
- Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y, Seki N (2010). "miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC)". Br. J. Cancer. 103 (6): 877–84. doi:10.1038/sj.bjc.6605811. PMC 2966617. PMID 20700123.
- Wu H, Xiao Z, Zhang H, Wang K, Liu W, Hao Q (2014). "MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3". Anticancer Drugs. 25 (7): 799–809. doi:10.1097/CAD.0000000000000107. PMID 24686007. S2CID 205525849.
- Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, Cai Y, Li X, Xing H, Shi M, Chen Y, Bruce IC, Wang T, Jin L, Qi X, Hua D, Jin J, Ma X (2014). "MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway". FEBS Lett. 588 (11): 2009–15. doi:10.1016/j.febslet.2014.04.024. PMID 24786471. S2CID 21988931.
- Patel Y, Soni M, Awagulerwitsch A, Kern MJ, Liu S, Shah N, Singh UP, Chen H (August 2018). "Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis". Oncogene. 38 (3): 445–453. doi:10.1038/s41388-018-0439-1. PMC 6338493. PMID 30104710.
- Patel Y, Lee JS, Chen H (June 2016). "Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization". Journal of Visualized Experiments (112). doi:10.3791/53928. PMC 4922489. PMID 27341462.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.